Early detection of CKD: the benefits, limitations and effects on prognosis

被引:75
作者
Levin, Adeera [1 ]
Stevens, Paul E. [2 ]
机构
[1] Univ British Columbia, Div Nephrol, Vancouver, BC V6Z 1Y8, Canada
[2] E Kent Hosp Univ, Natl Hlth Serv Fdn Trust, Kent Kidney Care Ctr, Canterbury CT1 3NG, Kent, England
关键词
CHRONIC KIDNEY-DISEASE; ACUTE-RENAL-FAILURE; GLOMERULAR-FILTRATION-RATE; CARDIOVASCULAR RISK-FACTORS; ACUTE MYOCARDIAL-INFARCTION; COST-EFFECTIVENESS; DIABETES-MELLITUS; HEART-FAILURE; CYSTATIN C; CARE;
D O I
10.1038/nrneph.2011.86
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The past decade has seen an increasing focus on chronic kidney disease (CKD) and its attendant complications, which has resulted in improved understanding of their impact on health-care resources. The early detection of CKD has been facilitated by the implementation of routine reporting of estimated glomerular filtration rates (eGFRs) and by education of primary care physicians on the implications of detecting a decreased eGFR with respect to patient safety as well as to cardiovascular and renal outcomes. The goals of early CKD detection are to prevent CKD progression and associated complications, thus improving patient outcomes and reducing the impact of CKD on health-care resources. This Review examines the benefits of the early detection of CKD, and describes the limitations of current knowledge with respect to screening, early detection and treatment, as well as the unintended consequences of detection. In addition, this article highlights what is currently known about cardiovascular and renal outcomes and the effects of intervention in patients with CKD.
引用
收藏
页码:446 / 457
页数:12
相关论文
共 123 条
[1]   The early impact of the United Kingdom Chronic Kidney Disease (CKD) guidelines on the number of new attendances at renal clinics [J].
Aghaie-Jaladerany, H. ;
Cowell, D. ;
Geddes, C. C. .
SCOTTISH MEDICAL JOURNAL, 2007, 52 (04) :28-31
[2]   Chronic kidney disease associated mortality in diastolic versus systolic heart failure: A propensity matched study [J].
Ahmed, Ali ;
Rich, Michael W. ;
Sanders, Paul W. ;
Perry, Gilbert J. ;
Bakris, George L. ;
Zile, Michael R. ;
Love, Thomas E. ;
Aban, Inmaculada B. ;
Shlipak, Michael G. .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (03) :393-398
[3]   Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes [J].
Al Suwaidi, J ;
Reddan, DN ;
Williams, K ;
Pieper, KS ;
Harrington, RA ;
Califf, RM ;
Granger, CB ;
Ohman, EM ;
Holmes, DR .
CIRCULATION, 2002, 106 (08) :974-980
[4]  
Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365
[5]  
[Anonymous], DIAGN MAN CHRON KIDN
[6]  
[Anonymous], 1968, PUBLIC HLTH PAPERS
[7]  
[Anonymous], 2008, CHRON KIDN DIS NAT C
[8]   Five year clinical effect of coronary stenting and coronary artery bypass grafting in renal insufficient patients with multivessel coronary artery disease:: insights from ARTS trial [J].
Aoki, J ;
Ong, ATL ;
Hoye, A ;
van Herwerden, LA ;
Sousa, JE ;
Jatene, A ;
Bonnier, JJRM ;
Schönberger, JPMA ;
Buller, N ;
Bonser, R ;
Lindeboomo, W ;
Unger, F ;
Serruys, PW .
EUROPEAN HEART JOURNAL, 2005, 26 (15) :1488-1493
[9]   Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts [J].
Astor, Brad C. ;
Matsushita, Kunihiro ;
Gansevoort, Ron T. ;
van der Velde, Marije ;
Woodward, Mark ;
Levey, Andrew S. ;
de Jong, Paul E. ;
Coresh, Josef .
KIDNEY INTERNATIONAL, 2011, 79 (12) :1331-1340
[10]   Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of REnal and vascular ENdstage disease (PREVEND) study and the prevention of REnal and vascular ENdstage disease intervention trial (PREVEND IT) [J].
Atthobari, J ;
Asselbergs, FW ;
Boersma, C ;
de Vries, R ;
Hillege, HL ;
van Gilst, WH ;
Gansevoort, RT ;
de Jong, PE ;
de Jong-van den Berg, LTW ;
Postma, MJ .
CLINICAL THERAPEUTICS, 2006, 28 (03) :432-444